Browsing by Author Katsifis, A

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 7 to 26 of 55 < previous   next >
Issue DateTitleAuthor(s)
26-Mar-2007Decreased vesicular acetylcholine transporter and α4β2 nicotinic receptor density in the rat brain following 192 IgG-saporin immunolesioningQuinlivan, M; Chalon, S; Vergote, J; Henderson, J; Katsifis, A; Kassiou, M; Guilloteau, D
1-Dec-2010Detection and quantification of remote microglial activation in rodent models of focal ischaemia using the TSPO radioligand CLINDE.Arlicot, N; Petit, E; Katsifis, A; Toutain, J; Divoux, D; Bodard, S; Roussel, S; Guilloteau, D; Bernaudin, M; Chalon, S
29-Jun-2007Detection of apoptotic cell death in the thymus of dexamethasone treated rats using [123I]Annexin V and in situ oligonucleotide ligationZavitsanou, K; Nguyen, VH; Greguric, I; Chapman, J; Ballantyne, P; Katsifis, A
1-Apr-2012Development and validation of competition binding assays for affinity to the extracellular matrix receptors, αvβ3 and αIIbβ3 integrinSzabo, A; Howell, NR; Pellegrini, PA; Greguric, I; Katsifis, A
11-Oct-2010Development of [18F]-Flumazenil-PET for localisation of the epileptogenic zone in patients with medically refractory focal epilepsy.Vivash, L; Gregoire, MC; Dedeurwaerdere, S; Bouilleret, V; Roselt, P; Lau, EW; Ware, RE; Binns, D; Katsifis, A; Hicks, RJ; Myers, DE; O'Brien, TJ
1-Aug-2012Different radiolabelling methods alter the pharmacokinetic and biodistribution properties of Plasminogen Activator Inhibitor Type 2 (PAI-2) formsRanson, M; Berghofer, PJ; Vine, KL; Greguric, I; Shepherd, R; Katsifis, A
1-May-2011Differential behavioural and neurochemical outcomes from chronic paroxetine treatment in adolescent and adult rats: a model of adverse antidepressant effects in human adolescents?Karanges, E; Li, KM; Motbey, CP; Callaghan, PD; Katsifis, A; McGregor, IS
10-Sep-2009Discovery of [F-18]N-(2-(Diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance.Greguric, I; Taylor, SR; Denoyer, D; Ballantyne, P; Berghofer, PJ; Roselt, P; Pham, TQ; Mattner, F; Bourdier, T; Neels, OC; Dorow, DS; Loc'h, C; Hicks, RJ; Katsifis, A
1-Aug-2011Evaluation of [I-123]-CLINDE as a potent SPECT radiotracer to assess the degree of astroglia activation in cuprizone-induced neuroinflammation.Mattner, F; Bandin, DL; Staykova, M; Berghofer, PJ; Gregoire, MC; Ballantyne, P; Quinlivan, M; Fordham, S; Pham, TQ; Willenborg, DO; Katsifis, A
7-Jun-2008Evaluation of CLINDE as potent translocator protein (18 kDa) SPECT radiotracer reflecting the degree of neuroinflammation in a rat model of microglial activationArlicot, N; Katsifis, A; Garreau, L; Mattner, F; Vergote, J; Duval, S; Bodard, S; Guilloteau, D; Chalon, S
1-Jul-2011Fully automated one-pot radiosynthesis of O-(2-[18F]fluoroethyl)-L-tyrosine on the TracerLab FXFN moduleBourdier, T; Greguric, I; Roselt, P; Jackson, T; Faragalla, J; Katsifis, A
Mar-2010High-contrast PET of melanoma using F-18-MEL050, a selective probe for melanin with predominantly renal clearance.Denoyer, D; Greguric, I; Roselt, P; Neels, OC; Aide, N; Taylor, SR; Katsifis, A; Dorow, DS; Hicks, RJ
14-Jun-2007Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA – first small animal PET resultsReischl, G; Dorow, D; Cullinane, C; Katsifis, A; Roselt, P; Binns, D; Hicks, R
1-Jan-2011Improved detection of regional melanoma metastasis using 18F-6-Fluoro-N-[2-(Diethylamino)Ethyl] Pyridine-3-Carboxamide, a Melanin-specific PET probe, by perilesional administration.Denoyer, D; Potdevin, T; Roselt, P; Neels, OC; Kirby, L; Greguric, I; Katsifis, A; Dorow, DS; Hicks, RJ
6-Aug-2007In vivo imaging of brain lesions with [11C]CLINME, a new PET radioligand of peripheral benzodiazepine receptorsBoutin, H; Chauveau, F; Thominiaux, C; Kuhnast, B; Gregoire, MC; Jan, S; Trebossen, R; Dolle, F; Tavitian, B; Mattner, F; Katsifis, A
1-May-2010In vivo imaging of neuroinflammation: a comparative study between [F-18]PBR111, [C-11]CLINME and [C-11]PK11195 in an acute rodent model.Van Camp, N; Boisgard, R; Kuhnast, B; Thézé, B; Viel, T; Grégoire, M C; Chauveau, F; Boutin, H; Katsifis, A; Dolle, F; Tavitian, B
21-Jan-2014In vivo measurement of hippocampal GABAA/cBZR density with [18F]-Flumazenil PET for the study of disease progression in an animal model of temporal lobe epilepsyVivash, L; Gregoire, MC; Bouilleret, V; Berard, A; Wimberley, C; Binns, D; Roselt, P; Katsifis, A; Myers, DE; Hicks, RJ; O'Brien, TJ; Dedeurwaerdere, S
1-Jul-2011In vivo pharmacokinetics of radioiodinated urokinase plasminogen activator (uPA) inhibitors for imaging metastatic cancer.Berghofer, PJ; Greguric, I; Shepherd, R; Katsifis, A; Ranson, M; Vine, K
1-Feb-2008In vivo tracking of dendritic cells in patients with multiple myelomaPrince, HM; Wall, DM; Ritchie, D; Honemann, D; Harrisson, S; Quach, H; Thompson, M; Hicks, R; Lau, EW; Davison, J; Loudovaris, B; Bartholeyns, J; Katsifis, A; Mileshkin, L; Moloney, J; Loveland, B
Jun-2009In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat.Dedeurwaerdere, S; Gregoire, MC; Vivash, L; Roselt, P; Binns, D; Fookes, CJR; Greguric, I; Pham, TQ; Loc'h, C; Katsifis, A; Hicks, RJ; O'Brien, TJ; Myers, DE